Nemaura Medical INC

Nemaura Medical is outsourcing its remaining operations, leading to the departure of its COO and a board member, while seeking partnerships and non-dilutive funding.

Nemaura Medical Inc. shareholders have approved a reverse stock split of its common stock with a ratio between 1-for-10 and 1-for-150.

Nemaura Medical Inc. has increased its authorized common stock from 42 million to 62 million shares after receiving shareholder approval.

Nemaura Medical Inc. has converted $314,000 of debt into 4,000,000 shares of common stock and issued 7,452,300 shares to its CEO in lieu of salary and bonus payments, while also appointing two new board members.

Nemaura Medical Inc. held its annual meeting of stockholders on February 26, 2024, where directors were elected, the accounting firm was ratified, and an increase in authorized shares was approved.

Nemaura Medical reports a net loss for Q3 2024, continues to advance its sugarBEAT device, and shifts its FDA strategy.